diagnostic delay reported 152 (62% of cases) outcome of treatment reported for 214 (88%) of cases AFB = acid-fast bacilli; HIV = human immunodeficiency virus; OR = odds ratio; TB = tuberculosis; TST = tuberculin skin test; WHO = World Health Organization Table 99 Study profiles of included studies on the effectiveness of change in management due to rifampicin-resistance mutations being identified Study setting Study design Study population Selection criteria Intervention Comparator Outcomes Quality appraisal Drobniewski et al. () Cohort study N=90 MDR-TB patients Inclusion Treatment with at Treatment with Median survival period least three drugs fewer drugs to UK Level: III-2 36 born in UK, 7 in Pakistan, All mycobacterial cultures identified Chance of death to which the which the 5 in India, 4 in Bangladesh, by the Public Health Laboratory Quality: 19/26 bacterium was bacterium was 20 in Africa, 4 in Europe, 1 Service, Mycobacterium Reference Some risk of bias susceptible susceptible each from USA, Australia, Unit, Scottish Mycobacteria Philippines, Japan, Trinidad, Reference Laboratory, and PHLS Jamaica Regional Centres for Mycobacteria All cases were to at least isoniazid and RIF, and 29 and 33 cases were resistant to pyrazinamide and ethambutol, respectively Lam et al. () Retrospective chart N=190 RIF-resistant or Inclusion Treatment other Category II Odds for poor outcome review patients than Category II treatment (treatment fail, death) Thailand Patients with DST results (streptomycin, Level: III-2 demonstrating infection with isoniazid, or MDR-TB who were Quality: 18.5/26 ethambutol, RIF registered for TB treatment during Some risk of bias and October 2004 – September 2008 at pyrazinamide) health facilities within the Thailand TBAactive Surveillance Network Exclusion Patients from health facilities operated by private practitioners,
diagnostic delay reported 152 (62% of cases) outcome of treatment reported for 214 (88%) of cases AFB = acid-fast bacilli; HIV = human immunodeficiency virus; OR = odds ratio; TB = tuberculosis; TST = tuberculin skin test; WHO = World Health Organization Table 99 Study profiles of included studies on the effectiveness of change in management due to rifampicin-resistance mutations being identified Study setting Study design Quality appraisal Study population Selection criteria Intervention Comparator Outcomes Drobniewski et al. () UK Cohort study Level: III-2 Quality: 19/26 Some risk of bias N=90 MDR-TB patients 36 born in UK, 7 in Pakistan, 5 in India, 4 in Bangladesh, 20 in Africa, 4 in Europe, 1 each from USA, Australia, Philippines, Japan, Trinidad, Jamaica All cases were to at least isoniazid and RIF, and 29 and 33 cases were resistant to pyrazinamide and ethambutol, respectively Inclusion All mycobacterial cultures identified by the Public Health Laboratory Service, Mycobacterium Reference Unit, Scottish Mycobacteria Reference Laboratory, and PHLS Regional Centres for Mycobacteria Treatment with at least three drugs to which the bacterium was susceptible Treatment with fewer drugs to which the bacterium was susceptible Median survival period Chance of death Lam et al. () Thailand Retrospective chart review Level: III-2 Quality: 18.5/26 Some risk of bias N=190 RIF-resistant or patients Inclusion Patients with DST results demonstrating infection with or MDR-TB who were registered for TB treatment during October 2004 – September 2008 at health facilities within the Thailand TBAactive Surveillance Network Exclusion Patients from health facilities operated by private practitioners, Treatment other than Category II Category II treatment (streptomycin, isoniazid, ethambutol, RIF and pyrazinamide) Odds for poor outcome (treatment fail, death)
1234_FinalAssessmentReport-accessible.docx